IMTITHAL ALAZZAWI

[AJKD @AJKDonline]

Urinary CXCL9 and CXCL10, Interstitial Inflammation and Disease Activity Over Time in Acute Interstitial Nephritis

https://t.co/iStQzVfWsZ (OPEN ACCESS)

@olivieraubert_ @bertperso @DanyAnglicheau @MRabant @BoudhabhayI

[Grace Choung, MD 박영이 @grace_choung]

Complement in Kidney Disease: Core Curriculum 2026 - American Journal of Kidney Diseases https://t.co/C2hmAQQSFi

[American Society of Pediatric Nephrology @ASPNeph]

Can urinary albumin-creatinine ratio be used as a surrogate for protein-creatinine ratio in the diagnosis and management of pediatric steroid sensitive nephrotic syndrome? @ped_neph

https://t.co/Di7f7QAOBV

[KDIGO @goKDIGO]

Please note: The public review period for the draft of the KDIGO AKI/AKD Guideline has been extended through Monday, May 11, 2026.

Visit the guideline website to download the public review draft and submit comments via the feedback form: https://t.co/BZhbUxUkdn

This guideline represents the first major update to the KDIGO AKI Guideline since 2012 and reflects substantial advances in the understanding, detection, and management of acute kidney disorders. It introduces an expanded framework that encompasses both AKI and AKD, recognizing the continuum of kidney injury, recovery, and risk of chronic kidney disease.

We recognize that your time is limited, so you are welcome to focus your review on the sections most relevant to your expertise. All comments are appreciated. By submitting comments, you agree that KDIGO may acknowledge your contribution as a reviewer in the final publication.

[KIReports @KIReports]

1/ Hey #NephTwitter!👋
We’re back with a fresh #XTorial
We spend half our lives worrying about how bad creatinine is.. then keep using it anyway.
What if we could measure GFR at the bedside - no serial blood samples? Let’s talk transdermal GFR (tGFR).
#MedTwitter @ISNkidneycare

[KIReports @KIReports]

4/📍Our #Tweetorial is about Stopping progression in ADPKD and VA by @KajareeG

[AJKD @AJKDonline]

Current and Future Therapeutics for Focal Segmental Glomerular Sclerosis in the Era of Precision Medicine: A Review

https://t.co/RkHblc7Bg6 (OPEN ACCESS)

[American Journal of Hypertension @amjhypertension]

State of the Art Review
The Rapid Evolution of Continuous Blood Pressure Measurement: Future Considerations

https://t.co/Wwhn0amvFD

[Arvind Canchi (Conjeevaram)🇮🇳 @arvindcanchi]

Prevention of Urinary Stones with Hydration - PUSH Trial
1. Didn't work
2. Tough to get pts to drink more water.
The PUSH Trial in Lancet - https://t.co/z3FeZofyKs
A nice synopsis of the trial here - https://t.co/UsgpNWNeCh

[CKJ @CKJsocial]

SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art

https://t.co/gcfaOAsQHS

[Samuel Hume @DrSamuelBHume]

How outcomes in relapsed/refractory multiple myeloma changed, from 1986 to 2026

[Kelly Haughton, MD @kidneydoctorpa]

IgA nephropathy progresses to kidney failure in up to 50% of patients within 10–20 years.

On March 29th, the NEJM published the final 24-month data from APPLAUSE-IgAN and the results change the treatment landscape.

Here’s what every nephrologist needs to know 🧵

Barratt J et al. NEJM 2026. DOI: 10.1056/NEJMoa2600743

[Katalin Susztak @KSusztak]

Another win for nephrology ! Complement inhibitors in IgAN ! Iptacopan in IgA Nephropathy — Final 24-Month Data | @NEJM https://t.co/eZq4zi4Irb

[Transplantation @TransplantJrnl]

This review by Cantarelli et al. highlights how EPO promotes tolerance, dampens inflammation, and shapes T cells and macrophages in kidney disease and #transplantation. #TXPforAll #Immunology https://t.co/JzdW4p46kW

[Hans-Joachim Anders @hjanders_hans]

Now online at @NDTsocial

Efficacy and safety of belimumab in IgAN: real-world evidence

🧐BEL was associated with higher proteinuria remission rates in pts with IgAN, without an increased incidence of common adverse events

▶️https://t.co/2xovyLXW0h

[𝐉𝐨𝐬𝐞𝐩𝐡 𝐅𝐥𝐲𝐧𝐧, 𝐌𝐃 @drjosflynn]

Hydroxychloroquine use in pediatric IgA nephropathy
https://t.co/QVCRdoUyrb
@ASPNeph @ESPN_Society

[NDT @NDTsocial]

The evolution of symptom burden in older men and women with advanced CKD

https://t.co/tythZRKDUm

[ASN Publications @asnpublications]

New #ASNCJASN Podcast: Dr. Saland summarizes the main findings from his study on "Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1" Listen here: https://t.co/zCf4L0fjmt

[AIN/Sandipan Shringi @Nephrosage]

Treatment standard: CKD in the geriatric patient
More info: https://t.co/LvS2fCQtVg
@NDTsocial, @vinckcaro, @hjanders_hans, @ERAkidney